← BLACKLEDGER Content Feed

Selling • NEUROPHAGE x BLACKLEDGER • 8 min read • 2026-07-28

BLACKLEDGER Selling Watch: SOL, XRP, SUI

BLACKLEDGERMarket ResearchSellingSOLXRPSUIDNN
BLACKLEDGER Selling public market research update for SOL, XRP, SUI

BLACKLEDGER's latest selling watch update tracks SOL, XRP, SUI, DNN, CRSP, RXRX from the active public watchlist. This post is built from public-safe status data, in-house public signal labels, and outside public source context. It is designed to help readers understand what is happening around each asset without exposing private research methods.

Selling Watch Data

The dedicated feed category for this update is Selling. The latest public scan timestamp is 2026-07-28T08:00:27.282429+00:00.

Educational Context: How To Use This Page

This page is not a trade instruction. It is an educational research brief. Readers can use it to understand company or project background, public market context, public status labels, and relevant outside-source headlines before doing their own due diligence.

SOL Public Research Bio

Name: Solana USD. Market class: crypto. Public bias: Bear. Public tier: Extended.

Solana (SOL) is a cryptocurrency launched in 2020. Solana has a current supply of 631,122,301.30719829 with 583,094,076.2722249 in circulation. The last known price of Solana is 73.28416731 USD and is down -3.92 over the last 24 hours. It is currently trading on 1148 active market(s) with $2,003,079,963.77 traded over the last 24 hours. More information can be found at https://solana.com.

Why SOL Is In This Public Update

Outside Public Headlines / Source Notes

XRP Public Research Bio

Name: XRP USD. Market class: crypto. Public bias: Bear. Public tier: Extended.

XRP (XRP) is a cryptocurrency . XRP has a current supply of 99,985,635,707 with 62,533,271,955 in circulation. The last known price of XRP is 1.05870497 USD and is down -4.38 over the last 24 hours. It is currently trading on 1852 active market(s) with $1,333,081,625.05 traded over the last 24 hours. More information can be found at https://xrpl.org/.

Why XRP Is In This Public Update

Outside Public Headlines / Source Notes

SUI Public Research Bio

Name: Salmonation USD. Market class: crypto. Public bias: Bear. Public tier: Extended.

Salmonation (SUI) is a cryptocurrency launched in 2022. Salmonation has a current supply of 100,000,000 with 0 in circulation. The last known price of Salmonation is 0.00030019 USD and is up 0.00 over the last 24 hours. It is currently trading on 9 active market(s) with $0.00 traded over the last 24 hours. More information can be found at https://salmonchain.com.

Why SUI Is In This Public Update

Outside Public Headlines / Source Notes

DNN Public Research Bio

Deep bio flag: This asset reached the 9+ public rating threshold, so BLACKLEDGER includes a fuller company/project profile, outside-source context, and public education notes.

Name: Denison Mines Corp.. Market class: stock. Public bias: Bear. Public tier: Extended.

Denison Mines Corp. engages in the acquisition, exploration, and development of uranium bearing properties in Canada. It holds 95% interest in its flagship project Wheeler River uranium project located in the Athabasca Basin region in northern Saskatchewan. The company was formerly known as International Uranium Corporation and changed its name to Denison Mines Corp. in December 2006. The company was founded in 1954 and is headquartered in Toronto, Canada.

Why DNN Is In This Public Update

Outside Public Headlines / Source Notes

CRSP Public Research Bio

Deep bio flag: This asset reached the 9+ public rating threshold, so BLACKLEDGER includes a fuller company/project profile, outside-source context, and public education notes.

Name: CRISPR Therapeutics AG. Market class: stock. Public bias: Bear. Public tier: Extended.

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo, and type 1 diabetes, as well as develops investigational CAR T programs, including an autologous, gene-edited CAR T program targeting allogeneic chimeric antigen receptor T cell for autoimmune indications and oncology. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease (SCD), and hemog

Why CRSP Is In This Public Update

Outside Public Headlines / Source Notes

RXRX Public Research Bio

Deep bio flag: This asset reached the 9+ public rating threshold, so BLACKLEDGER includes a fuller company/project profile, outside-source context, and public education notes.

Name: Recu[redacted]on Pharmaceuticals, Inc.. Market class: stock. Public bias: Bear. Public tier: Extended.

Recu[redacted]on Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat biomarker-enriched solid tumors and lymphoma; REC-3565 that is in Phase 1/2 for the treatment of relapsed or refractory B-cell malignancies; and REC-4539, a reve[redacted]ble, CNS penetrant, orally bioavailable, and potential best-in-class inhibitor of LSD1 for the treatment of solid tumors and h[redacted]tology oncology. Its preclinical stage product includes REC-7735 for the treatment of

Why RXRX Is In This Public Update

Outside Public Headlines / Source Notes

What The Public Data Shows

The public feed highlights ticker status, market class, directional bias, score, tier, confidence, company or project profile, public market references, and outside-source headlines. These fields support a deeper view of BLACKLEDGER's public research feed while keeping private methods undisclosed.

Why This Category Matters

The Selling section gives readers a focused path through the market: buying watch content for constructive candidates, selling watch content for defensive movement, investing content for higher-quality public watch names, and market trend notes for broader context.

Research-Only Notice

BLACKLEDGER content is market research only. There is no live execution signal, no recommendation to buy or sell, and no financial advice. Readers should perform their own due diligence and consult licensed professionals before making financial decisions.

Research-only. No execution signal. Not financial advice.